Chemomab Therapeutics (CMMB) Total Liabilities (2017 - 2025)

Chemomab Therapeutics' Total Liabilities history runs 9 years deep, the most recent figure standing at $1.5 million for Q4 2025.

• Quarterly Total Liabilities fell 56.87% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (down 56.87% YoY) and the FY2025 annual result came in at $1.5 million, down 56.87% from the prior year.
• Total Liabilities was $1.5 million for Q4 2025 at Chemomab Therapeutics, up from $1.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $7.1 million in Q1 2023 and bottomed at $1.1 million in Q3 2025.
• A 5-year average of $4.1 million and a median of $4.6 million in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities surged 190.2% — and 2025, when it plunged 75.17%.
• Chemomab Therapeutics' Total Liabilities stood at $2.9 million in 2021, then jumped by 136.92% to $6.8 million in 2022, then fell by 24.65% to $5.2 million in 2023, then slumped by 33.51% to $3.4 million in 2024, then tumbled by 56.87% to $1.5 million in 2025.
• Business Quant data shows CMMB's Total Liabilities at $1.5 million in Q4 2025, $1.1 million in Q3 2025, and $1.4 million in Q2 2025.